Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
Daily Summary: ๐ A Red Day Across Markets. AI Sector Weighs on Wall Street, Precious Metals Under Pressure
Stock of the Week: ASML โ The Machines Driving the Future of Semiconductors
Netflix down 45% from its peak ๐ฉ What will the streaming giant's earnings reveal?
US Open: Blood on Wall Street as Semiconductor Sector Extends Correction